{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:03Z","timestamp":1792788483154,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["OT2OD032644"],"award-info":[{"award-number":["OT2OD032644"]}]},{"name":"NIH","award":["R01EY016323"],"award-info":[{"award-number":["R01EY016323"]}]},{"name":"NIH","award":["R01EY033847"],"award-info":[{"award-number":["R01EY033847"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To analyze the therapeutic response to faricimab 6\u00a0mg\/0.05\u00a0ml in eyes with neovascular AMD (nAMD) with refractory intra- and\/or subretinal fluid due to choroidal neovascularization (CNV), previously unresponsive to 4\u00a0mg monthly aflibercept and combination therapy with anti-VEGF and long-acting steroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective case series study of 22 eyes with unresponsive CNV, despite monthly intravitreal treatment (mean number of pre-faricimab injections: 35.52\u2009\u00b1\u200917.12). We evaluated therapeutic response in eyes with persistent intra\/subretinal fluid (IRF\/SRF) unresponsive to anti-VEGF double-dose (DD) monotherapy (4-mg aflibercept) and\/or simultaneous DD anti-VEGF (4-mg aflibercept) with steroids (triamcinolone). Best-corrected visual acuity (BCVA), intraocular pressure (IOP), and optical coherence tomography (OCT) measurements of central retinal thickness (CRT) were recorded for 7 follow-ups. Baseline and follow-up OCTs were examined by an AI-developed platform (Discovery OCT Fluid and Biomarker Detector, RetinAI AG, Switzerland) to measure the volume of IRF, SRF, and pigment epithelium detachment (PED) in nanoliters (nL) and CRT in micrometers (\u03bcm). Paired t-test compared these parameters at baseline and after treatment. OCTA analysis of CNV before and after treatment with faricimab was conducted using Angio-Tool software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anatomic outcomes included mean CRT reduction of -25.3\u00a0\u03bcm (p\u2009=\u20090.0118) at month-1, -16.15\u00a0\u03bcm (p\u2009=\u20090.0414) at month-4, and -26.36\u00a0\u03bcm (p\u2009=\u20090.0129) after the 7th follow-up. AI-assisted software analysis showed a significant reduction of IRF, SRF, and PED volume at multiple time points after initiating faricimab. There was a non-significant improvement in BCVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to faricimab improved anatomy in highly treatment-resistant CNV eyes, indicating its potential when other therapeutic options have failed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00691-4","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:27:53Z","timestamp":1750163273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA"],"prefix":"10.1186","volume":"11","author":[{"given":"Anna","family":"Heinke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Warter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines D.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Agnihotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal Nailesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Miguel B.","family":"Galang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Deussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Uwe G.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry A.","family":"Ferreyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"691_CR1","unstructured":"Hobbs SD, Pierce K. Wet Age-related macular degeneration (wet AMD). StatPearls. Treasure Island. 2023."},{"issue":"2","key":"691_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/aos.15233","volume":"101","author":"H Haji","year":"2023","unstructured":"Haji H, Gianniou C, Brynskov T, Sorensen TL, Olsen R, Krogh NM. Association between structural and functional treatment outcomes in neovascular age-related macular degeneration. Acta Ophthalmol. 2023;101(2):177\u201384.","journal-title":"Acta Ophthalmol"},{"issue":"14","key":"691_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"key":"691_CR4","doi-asserted-by":"crossref","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116 (1):57\u201365 e5.","DOI":"10.1016\/j.ophtha.2008.10.018"},{"issue":"3","key":"691_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3109\/08820538.2011.577130","volume":"26","author":"SM Couch","year":"2011","unstructured":"Couch SM, Bakri SJ. Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol. 2011;26(3):114\u201320.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"691_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/138945011794182719","volume":"12","author":"RA Das","year":"2011","unstructured":"Das RA, Romano A, Chiosi F, Menzione M, Rinaldi M. Combined treatment modalities for age related macular degeneration. Curr Drug Targets. 2011;12(2):182\u20139.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"691_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/138945011794182746","volume":"12","author":"EM Becerra","year":"2011","unstructured":"Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011;12(2):149\u201372.","journal-title":"Curr Drug Targets"},{"issue":"9","key":"691_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3928\/23258160-20170829-06","volume":"48","author":"IK Muftuoglu","year":"2017","unstructured":"Muftuoglu IK, Tsai FF, Lin T, Freeman WR. High-dose decanted triamcinolone for treatment-resistant persistent macular edema. Ophthalmic Surg Lasers Imaging Retina. 2017;48(9):717\u201326.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"691_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicolo","year":"2021","unstructured":"Nicolo M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30(3):193\u2013200.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"691_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1(4): 100076.","journal-title":"Ophthalmol Sci"},{"issue":"17","key":"691_CR11","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye. 2023;37(17):3574\u201381.","journal-title":"Eye"},{"key":"691_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"issue":"15","key":"691_CR13","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valentin-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye. 2023;37(15):3282\u20139.","journal-title":"Eye"},{"issue":"6","key":"691_CR14","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1097\/IAE.0000000000001726","volume":"38","author":"QS You","year":"2018","unstructured":"You QS, Gaber R, Meshi A, Ramkumar HL, Alam M, Muftuoglu IK, et al. High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration. Retina. 2018;38(6):1156\u201365.","journal-title":"Retina"},{"issue":"10","key":"691_CR15","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00417-017-3734-6","volume":"255","author":"IK Muftuoglu","year":"2017","unstructured":"Muftuoglu IK, Freeman WR. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(10):2069.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"691_CR16","doi-asserted-by":"crossref","unstructured":"Habra O, Gallardo M, Meyer Zu Westram T, De Zanet S, Jaggi D, Zinkernagel M, et al. Evaluation of an Artificial Intelligence-Based Detector of Sub- and Intraretinal Fluid on a Large Set of Optical Coherence Tomography Volumes in Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmologica. 2022; 245 (6):516\u201327.","DOI":"10.1159\/000527345"},{"issue":"4","key":"691_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.10.4.17","volume":"10","author":"I Mantel","year":"2021","unstructured":"Mantel I, Mosinska A, Bergin C, Polito MS, Guidotti J, Apostolopoulos S, et al. Automated quantification of pathological fluids in neovascular age-related macular degeneration, and its repeatability using deep learning. Transl Vis Sci Technol. 2021;10(4):17.","journal-title":"Transl Vis Sci Technol"},{"key":"691_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82: 100906.","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"691_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8(6):537\u201344.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"691_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/bjophthalmol-2018-313447","volume":"104","author":"T Lin","year":"2020","unstructured":"Lin T, Dans KC, Muftuoglu IK, Meshi A, Amador-Patarroyo MJ, Cheng L, et al. Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Br J Ophthalmol. 2020;104(1):58\u201363.","journal-title":"Br J Ophthalmol"},{"key":"691_CR21","doi-asserted-by":"crossref","unstructured":"Szigiato A, Mohan N, Talcott KE, Mammo DA, Babiuch AS, Kaiser PK, et al. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy. Ophthalmol Retina. 2023.","DOI":"10.1016\/j.oret.2023.08.018"},{"issue":"4","key":"691_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/2474126419895692","volume":"4","author":"JH Powers","year":"2020","unstructured":"Powers JH, Wisely CE, Sastry A, Fekrat S. Prompt improvement of an enlarging pigment epithelial detachment following intravitreal dexamethasone in neovascular age-related macular degeneration. J Vitreoretin Dis. 2020;4(4):327\u201331.","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"691_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2018-000244","volume":"4","author":"L Faes","year":"2019","unstructured":"Faes L, Ali Z, Wagner S, Patel PJ, Fu DJ, Bachmann LM, et al. Effect of total anti-VEGF treatment exposure on patterns of choroidal neovascularisation assessed by optical coherence tomography angiography in age-related macular degeneration: a retrospective case series. BMJ Open Ophthalmol. 2019;4(1): e000244.","journal-title":"BMJ Open Ophthalmol"},{"issue":"11","key":"691_CR24","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1097\/IAE.0000000000000836","volume":"35","author":"NW Muakkassa","year":"2015","unstructured":"Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina. 2015;35(11):2252\u20139.","journal-title":"Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00691-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:27:55Z","timestamp":1750163275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00691-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00691-4","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UCSD Institutional Review Board (IRB Nr#120516) approval was acquired for the review and analysis of patient data. All procedures adhered to the tenets of the Declaration of Helsinki for research involving human subjects and complied with Health Insurance Portability and Accountability Act (HIPAA) regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}